Brief: Arch Biopartners Announces Non Brokered Private Placement Financing
26/01/2018 13:49
Jan 26 (Reuters) - Arch Biopartners:
* ARCH BIOPARTNERS ANNOUNCES NON BROKERED PRIVATE PLACEMENT
FINANCING
* ARCH BIOPARTNERS- INTENDS TO COMPLETE NON-BROKERED PRIVATE
PLACEMENT OFFERING OF UP TO 2.5 MILLION COMMON SHARES PRICED AT
$0.50 PER SHARE
* ARCH BIOPARTNERS - TO USE PORTION OF PROCEEDS TO FUND
INVESTIGATOR INITIATED PHASE I INHALATION SAFETY TRIAL CO IS
SPONSORING FOR AB569
* ARCH BIOPARTNERS INC - REMAINING PROCEEDS WILL BE USED TO
SUPPORT INVESTIGATIONAL NEW DRUG APPLICATION FOR METABLOK
Source text for Eikon: ID:nGNXOMQVLa
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide